Law360, New York (April 13, 2011, 7:33 PM ET) -- A group of third-party payors last month asked the U.S. Supreme Court to allow them to sue Eli Lilly & Co. over increased drug costs related to the company's alleged off-label and fraudulent marketing of its antipsychotic Zyprexa.
It does not make sense that government agencies and insurers should be able to recover $1.415 billion in fines, penalties and compensation over the marketing of Eli Lilly's Zyprexa while private insurers take nothing, a group of class action plaintiffs said in a petition filed Mar. 25 in...
Zyprexa Payors Ask High Court For Shot At Eli Lilly
To view the full article, take a free trial now.
